158 related articles for article (PubMed ID: 36733354)
1. HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients.
Cavalieri S; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Alfieri S; Quattrone P; Calareso G; Iacovelli NA; Franceschini M; Licitra L
Front Oncol; 2022; 12():1096068. PubMed ID: 36733354
[TBL] [Abstract][Full Text] [Related]
2. The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center.
Mayer M; Wolber P; Prinz J; Jansen L; Esser J; Shabli S; Quaas A; Klußmann JP; Sharma SJ; Nachtsheim L; Arolt C
Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3779-3789. PubMed ID: 38587651
[TBL] [Abstract][Full Text] [Related]
3. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG
Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report.
Yang ZY; Huang JH; Chen B; Xu CW; Lei L; Wang XJ; Fang MY
Front Oncol; 2020; 10():559057. PubMed ID: 33123470
[No Abstract] [Full Text] [Related]
5. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
[TBL] [Abstract][Full Text] [Related]
6. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.
McAfee JL; Hoda RS; Hoyle C; McCoy L; Sprague C; Reddy CA; Koyfman SA; Geiger JL; Komforti MK; Griffith CC
Mod Pathol; 2023 Oct; 36(10):100273. PubMed ID: 37423585
[TBL] [Abstract][Full Text] [Related]
7. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
[TBL] [Abstract][Full Text] [Related]
8. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Kawakita D; Nagao T; Takahashi H; Kano S; Honma Y; Hirai H; Saigusa N; Akazawa K; Tani K; Ojiri H; Tsukahara K; Ozawa H; Okami K; Kondo T; Togashi T; Fushimi C; Shimura T; Shimizu A; Okamoto I; Okada T; Imanishi Y; Watanabe Y; Otsuka K; Sakai A; Ebisumoto K; Sato Y; Yamazaki K; Ueki Y; Hanazawa T; Saito Y; Ando M; Matsuki T; Nakaguro M; Sato Y; Urano M; Utsumi Y; Kohsaka S; Saotome T; Tada Y
Ther Adv Med Oncol; 2022; 14():17588359221119538. PubMed ID: 36090801
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
10. Metastatic salivary duct carcinoma in cardiac and pleural effusions: A case report with immunocytochemical analysis for androgen receptor and HER2.
Ito H; Ishida M; Sando K; Okano K; Ebisu Y; Fujisawa T; Iwai H; Tsuta K
Mol Clin Oncol; 2019 Jan; 10(1):78-82. PubMed ID: 30655980
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
12. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
Locati LD; Perrone F; Losa M; Mela M; Casieri P; Orsenigo M; Cortelazzi B; Negri T; Tamborini E; Quattrone P; Bossi P; Rinaldi G; Bergamini C; Calderone RG; Liberatoscioli C; Licitra L
Oral Oncol; 2009 Nov; 45(11):986-90. PubMed ID: 19574086
[TBL] [Abstract][Full Text] [Related]
13. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
14. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
Liang L; Williams MD; Bell D
Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
[TBL] [Abstract][Full Text] [Related]
19. First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study.
Viscuse PV; Price KA; Garcia JJ; Schembri-Wismayer DJ; Chintakuntlawar AV
Front Oncol; 2019; 9():701. PubMed ID: 31428578
[No Abstract] [Full Text] [Related]
20. HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis.
Egebjerg K; Harwood CD; Woller NC; Kristensen CA; Mau-Sørensen M
Front Oncol; 2021; 11():693394. PubMed ID: 34249747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]